The BD2-selective inhibitor ABBV-744 (AbbVie) showed robust preclinical efficacy in AR-positive prostate cancer and AML models, displacing BRD4 from AR-containing super-enhancers, inhibiting AR-dependent transcription, and reducing tumor growth in xenografts. Here, BRD4 is linked to prostate carcinoma.